FIELD: pharmacology.
SUBSTANCE: group of inventions is a hemostatic sponge containing a freeze-dried substrate and active substance, characterized in that it contains sodium alginate as the base, and as an active ingredient fibrin monomer with the following ratio of the components in the final aqueous solution in the volume per 1 litre in wt %: Sodium alginate - 0.1-8.0, Fibrin-monomer - 0.01-0.5, as well as a method for obtaining a hemostatic sponge.
EFFECT: expansion of the assortment of hemostatic sponges and can be used to stop bleeding in surgical practice, in combat situations, in the aftermath of mass catastrophes and terrorist acts, and in combat situations.
4 cl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
HEMOSTATIC SOLUTION BASED ON SULFUSATED POLYSACCHARIDES AND THE HEMOSTATIC SPONGES PRODUCTION FROM THIS SOLUTION (OPTIONS) | 2017 |
|
RU2652270C1 |
HAEMOSTATIC SPONGE AND METHOD FOR ITS PREPARATION | 2016 |
|
RU2618896C1 |
HEMOSTATIC SPONGE (VERSIONS) | 2016 |
|
RU2627855C1 |
HAEMOSTATIC AGENT BASED ON POLYVINYLPYRROLIDONE AND METHODS FOR PREPARING ITS PHARMACOLOGICAL FORMS | 2018 |
|
RU2705812C1 |
HEMOSTATIC COATING IN FORM OF SPONGE OR FILM (VERSIONS) | 2016 |
|
RU2639379C1 |
HAEMOSTATIC POLYMER-BASED AGENT CONTAINING MICROPARTICLES AND IRON OXIDE NANOPARTICLES, AND METHODS FOR PREPARING PHARMACOLOGICAL FORMS THEREOF | 2020 |
|
RU2739490C1 |
HEMOSTATIC COATING IN THE FORM OF POWDER | 2017 |
|
RU2660582C1 |
WOUND COVER WITH HEMOSTATIC ACTION, AND METHOD FOR ITS PRODUCTION | 2016 |
|
RU2624242C1 |
HAEMOSTATIC AGENT | 2004 |
|
RU2275201C2 |
METHOD OF PRODUCING ARTIFICIAL SPONGES IN MICRO TUBES FOR IN VITRO LABORATORY TESTING | 2018 |
|
RU2701195C1 |
Authors
Dates
2017-08-22—Published
2016-06-30—Filed